vilanterol

Ligand id: 7353

Name: vilanterol

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 4
Rotatable bonds 16
Topological polar surface area 91.18
Molecular weight 485.17
XLogP 3.39
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Vilanterol is contained in medications alongside a corticosteroid (eg fluticasone furoate (PubChem CID 9854489 and vilanterol marketed as Breo Ellipta®) or an anticholinergic drug (umeclidinium and vilanterol marketed as Anoro Ellipta®). Both of these medications were approved by the US FDA in 2013 to treat chronic obstructive pulmonary disease (COPD). In Europe, the EMA has approved Relvar Ellipta® (fluticasone furoate and vilanterol) for asthma and COPD. In May 2015, the US FDA expanded approval of Breo Ellipta® to include treatment of asthma.
Mechanism Of Action and Pharmacodynamic Effects
Vilanterol is a long-acting β2-adrenoceptor agonist. Upon inhalation, the drug activates airway β2-adrenoceptors which causes vasodilation of airway smooth muscle and eases breathing. The corticosteroid component of the combination drug activates the glucocorticoid receptor (GR), helping to reduce the release of pro-inflammatory chemicals in the damaged lung, thereby futher aiding breathing.
External links